Anika Therapeutics Stock Annual Yield
| ANIK Stock | USD 17.72 0.52 3.02% |
Anika Therapeutics fundamentals help investors to digest information that contributes to Anika Therapeutics' financial success or failures. It also enables traders to predict the movement of Anika Stock. The fundamental analysis module provides a way to measure Anika Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Anika Therapeutics stock.
Anika | Annual Yield |
Anika Therapeutics Company Annual Yield Analysis
Anika Therapeutics' Yield generally refers to the amount of cash that is paid back to the owner of a security over a specific time (usually one year). It is expressed as a percentage of current market price, and usually amounts to all the interests and/or dividends paid over a given period. A higher yield allows the shareholders to generate returns on their investments sooner. However, investors should also be aware that a high yield may be a result of market turmoil or increased price volatility.
Anika Annual Yield Driver Correlations
Understanding the fundamental principles of building solid financial models for Anika Therapeutics is extremely important. It helps to project a fair market value of Anika Stock properly, considering its historical fundamentals such as Annual Yield. Since Anika Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Anika Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Anika Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Small firms, start-ups, or companies with high growth potential typically do not pay out dividends or distribute a lot of their profits. These companies will have small yield. Alternatively, more established companies, ETFs, and funds that invest in bonds will have higher yields.
| Competition |
In accordance with the recently published financial statements, Anika Therapeutics has an Annual Yield of 0.0%. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Did you try this?
Run Portfolio File Import Now
Portfolio File ImportQuickly import all of your third-party portfolios from your local drive in csv format |
| All Next | Launch Module |
Anika Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Anika Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Anika Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Anika Fundamentals
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.0401 | ||||
| Profit Margin | (0.59) % | ||||
| Operating Margin | (0.64) % | ||||
| Current Valuation | 213.7 M | ||||
| Shares Outstanding | 14.65 M | ||||
| Shares Owned By Insiders | 3.40 % | ||||
| Shares Owned By Institutions | 91.50 % | ||||
| Number Of Shares Shorted | 484.38 K | ||||
| Price To Earning | 42.30 X | ||||
| Price To Book | 1.38 X | ||||
| Price To Sales | 1.53 X | ||||
| Revenue | 166.66 M | ||||
| Gross Profit | 96.78 M | ||||
| EBITDA | 2.52 M | ||||
| Net Income | (82.67 M) | ||||
| Cash And Equivalents | 87.78 M | ||||
| Cash Per Share | 6.01 X | ||||
| Total Debt | 29.04 M | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 6.37 X | ||||
| Book Value Per Share | 12.24 X | ||||
| Cash Flow From Operations | (1.79 M) | ||||
| Short Ratio | 7.66 X | ||||
| Earnings Per Share | (6.73) X | ||||
| Price To Earnings To Growth | 1.91 X | ||||
| Target Price | 26.5 | ||||
| Number Of Employees | 357 | ||||
| Beta | 0.86 | ||||
| Market Capitalization | 251.9 M | ||||
| Total Asset | 270.63 M | ||||
| Retained Earnings | 128.05 M | ||||
| Working Capital | 132.25 M | ||||
| Current Asset | 176.43 M | ||||
| Current Liabilities | 17.28 M | ||||
| Net Asset | 270.63 M |
About Anika Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Anika Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Anika Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Anika Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Anika Therapeutics Piotroski F Score and Anika Therapeutics Altman Z Score analysis. For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anika Therapeutics. If investors know Anika will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anika Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.51) | Earnings Share (6.73) | Revenue Per Share 11.139 | Quarterly Revenue Growth (0.07) | Return On Assets (0.04) |
The market value of Anika Therapeutics is measured differently than its book value, which is the value of Anika that is recorded on the company's balance sheet. Investors also form their own opinion of Anika Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Anika Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anika Therapeutics' market value can be influenced by many factors that don't directly affect Anika Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anika Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Anika Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anika Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.